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Antibiotic resistance is widespread in respiratory pathogens.
The first report of penicillin resistance in the pneumococcus
was in 1967,1 and in 1977 multiply resistant pneumococci were
found in South Africa.2 Data from isolates submitted for
pneumococcal serotyping from children between 1995 and 1998
indicated overall antibiotic resistance rates of 38% and
penicillin resistance rates of 28.9%. 3 Alarmingly high resistance
rates were also found in pneumococci carried in the
nasopharynx of children attending private paediatric practices
in northern Johannesburg.4 In that study, resistance to any
antibiotic was found in 69.4% of sampled children, resistance to
penicillin in 42% and resistance to co-trimoxazole in 53.7%.
There is also clear evidence from developed countries of a
relationship between patterns of antibiotic use and
pneumococcal resistance to antibiotics.5
There are few data on patterns of antibiotic use in the face of
this global resistance epidemic and none from South Africa. We
therefore conducted a mail-out survey to determine the
common prescribing patterns for a variety of paediatric
conditions in South Africa.
What was done
Surveys
Bilingual (English and Afrikaans) surveys were mailed to 609
paediatricians registered in 1999 with the Health Professions
Council of South Africa (HPCSA). Included with each survey
was a covering letter explaining the survey and a stamped,
pre-addressed return envelope. The survey included questions
on paediatric practice, sources of information, and antibiotic
usage for specific paediatric illnesses. The paediatricians’
names were not included on the surveys to ensure
confidentiality of reporting.
Data analysis
Survey data were entered and analysed using EpiInfo
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could have tracked through an iatrogenic duodenal perforation
sustained at the time of ERCP and papillotomy is supported by
the anatomical descriptions outlined below.
The retroperitoneum4 is an actual space between the
posterior parietal peritoneum and the posterior abdominal
wall filled with loose areolar tissue. Although it has  no
bounds, it is limited superiorly by the diaphragm and
inferiorly by the levator muscles of the pelvic floor. Areas of
fusion exist in the midline, posteriorly around the major
anterior branches of the aorta, anteriorly and above the
semicircular line, to the posterior rectus sheath, and superiorly
to the anterior undersurface of the diaphragm and the
ligaments of the liver.
The gastrointestinal structures within the retroperitoneum
include the second, third and proximal fourth segment of the
duodenum, the pancreas, and the retropancreatic common bile
duct. There is therefore a potential communication with the
scrotal sac through the inguinal canal.
Our review of this case failed to reveal any other known
cause of the surgical emphysema nor has this been described
previously in the literature. The question remains — is this a
complication of ERCP? We believe it is.
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computer software.6 Ninety-five per cent confidence intervals
(95% CI) were calculated using JMP, Version 4 Statistical
Discovery Software.7
What was found
Of the 609 surveys mailed, 23 (4%) were returned by the post
office, 9 (1%) were returned but not completed by
paediatricians who had retired from clinical practice, and 112
surveys (18%) were returned and completed. The median age
of the respondents was 46 years (range 33 - 78 years), 93% had
received medical training in South Africa, 91% had done
specialty training in South Africa, 98% practised medicine in
urban areas, 62% practised medicine in the private sector, and
63% of the respondents served patients who had medical aid.
The majority of respondents obtained information on
antibiotic prescribing practices from the medical literature or
congresses/meetings, while half of those surveyed reported
using guidelines, summaries from pathology laboratories or
information from pharmaceutical representatives (Table I). The
choice of using antibiotics was influenced mainly by concerns
over antibiotic resistance and repeated episodes of the same
illness (Table II). Cost of treatment, lack of confirmation of the
aetiology, and inconvenience to patients of  having to return
should the problem persist were also of some importance.
Parental pressure and information from pharmaceutical
companies were of little importance in influencing treatment.
The antibiotic prescribing practices for individual illnesses
revealed the following. 
A beta-lactam antibiotic (including penicillin, amoxicillin
and amoxicillin/clavulanate) was the overwhelming choice for
treatment of penicillin-sensitive pneumococcal pneumonia
(91% of respondents, 95% CI: 84  - 95%); otitis media (96%, 
91 - 99%) and group A streptococcal pharyngitis (93%, 86 -
96%).  Cephalosporins were used most frequently to treat
penicillin-resistant pneumococcal disease (53%, 44 - 62% for
pneumonia, 49%, 39 - 58% for otitis media), and 47%, 38 - 56%
for Escherichia  coli urinary tract infections, while shigellosis
was treated with either a cephalosporin (36%, 28 - 45%) or
nalidixic acid (26%, 18 - 35%). Penicillins and amoxicillin were
still considered by a large percentage of respondents to be first-
line treatment for  penicillin-resistant otitis media (47%, 37 -
56%) and pneumonia (38%, 29 - 47%), while they are used less
frequently as first-line treatment for urinary tract infections
(28%, 20 - 37%) and for shigella dysentery (17%, 11 - 25%).
Macrolides were considered first-line agents by only a small
minority of respondents for penicillin-resistant pneumococcal
pneumonia (4%, 1 - 9%), and as second-line agents for
penicillin-resistant pneumococcal pneumonia and otitis media,
16% (10 - 25%) and 17% (10 - 26%) respectively. They were the
most important second-line agents for pharyngitis (39%, 29 -
50%).  Fluoroquinolones were only considered first line for
shigella dysentery by 11% of respondents (6 - 17%) and second
line by 10% (5 - 19%). Co-trimoxazole was considered a first- or
second-line agent by only a minority of respondents for the
treatment of  dysentery (7%, 4 - 14% first line; 13%, 7 - 22%
second line) and urinary tract infections (13%, 8 - 20% first line;
17%, 10 - 26% second line), and it was only rarely considered
first- or second line for the respiratory tract indications.  
Duration of therapy  ranged from 5 to 10 days for
pneumonia,  3 to 14 days for otitis media, 3 to 14 days for
pharyngitis, 5 to 10 days for dysentery and 5 to 21 days for
urinary tract infections. 
Table I. Sources of information regarding antibiotic prescribing
practices
% of respondents 
Source of information (95% CI) 
Pharmaceutical representatives 54 (44 - 62)
Medical literature 86 (77 - 90)
Summaries provided by pathology 
laboratories 59 (50 - 66)
Congresses/meetings 80 (71 - 86)
South African guidelines 54 (44 - 62)
CI = confidence interval.
Table II. Factors influencing decision to use antibiotic treatment (% (95% CI))
Very Average Least
Factor important importance important
Parental pressure 0 29 (21 - 38) 71 (61 - 79)
Information from pharmaceutical company 6 (3 - 12) 54 (4 - 64) 40 (31 - 49)
Inconvenient for patient to return if problem persists 10 (5 - 17) 71 (61 - 79) 19 (12 - 28)
Cost 16 (10 - 25) 71 (61 - 79) 13 (8 - 21)
Uncertain diagnosis 11 (6 - 19) 71 (61 - 79) 18 (12 - 27)
Repeated episodes of same illness 43 (34 - 53) 45 (36 - 55) 12 (7 - 20)
Concerns about antibiotic resistance 78 (69 - 85) 20 (13 - 28) 2 (0.5 - 7)
CI = confidence interval.
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Discussion
This survey was conducted to ascertain the antibiotic
prescribing practices of South African paediatricians. In light of
the current levels of antibiotic resistance in pneumococci
isolated from children in South Africa, we were hoping to
identify possible reasons for the increase in resistance levels
and potential areas for intervention. Treatment of
antimicrobial-resistant infections is estimated to cost the USA
more than $5 million each year.8 No data are available from
South Africa but use is likely to be increasing as the prevalence
of antibiotic-resistant infections increases. Austin et al.,9 using
population genetics and epidemiological modelling, showed
that the volume of antibiotic use impacts directly on the
prevalence of antibiotic resistance in the community. The
development of significant levels of resistance occurs at a
much faster rate than the decline in the prevalence of resistance
once antimicrobial use has been curtailed. Rapid intervention
is therefore necessary to curb increasing antimicrobial
resistance.
In addition to microbiological considerations, use of
antibiotics is influenced by cultural and economic factors.10
Patients may not be satisfied unless they receive some tangible
treatment after having made the effort to come to the physician
and having waited to be seen. Physicians may be unwilling to
send patients away with no treatment, and the choice of
treatment could be influenced by pharmaceutical company
marketing campaigns of newer antibiotics or formulations.
These did not appear to influence the respondents in our
survey.
Numerous studies have shown considerable misuse of
antibiotics stemming from diagnostic uncertainty, incorrect
choice of drug or improper use of a specific drug.10 The
inability to confirm the aetiology of the disease does appear to
play a role in the choice of treatment by South African
paediatricians. The South African Department of Health, in
conjunction with the World Health Organisation, has drafted
guidelines for the management of childhood illnesses.11 While
the guidelines do not cover all of the conditions in our survey,
there are recommendations for acute ear infections and
pneumonia (5 days of amoxycillin) and for dysentery (nalidixic
acid for 5 days). The antibiotic choices for antibiotic-sensitive
pneumococcal pneumonia and otitis media were consistent
with the guidelines; however, 70% of the respondents would
have treated for a longer duration, in most cases for 10 days.
Only a quarter of the respondents would have treated Shigella
dysentery with nalidixic acid; 80% of those choosing nalidixic
acid would treat for the recommended 5 days. Cephalosporins
appear to be the preferred treatment for many infections,
raising concern as to possible overuse of this class of
antibiotics. At approximately twice the cost, oral
cephalosporins are more expensive than beta-lactams such as
amoxicillin and overuse could shorten their efficacy through
the development of resistance. A total of 11% of the isolates
from children attending private practitioners in northern
Johannesburg were resistant to ceftriaxone.4
It is also of interest to compare the responses in this survey
with those of 24 academic South African paediatricians and
microbiologists.12 The treatment of pneumonia reported in this
study is similar to that of the academics, with a somewhat
greater emphasis again on the use of cephalosporins. The
academics were more aware of the use of nalidixic acid rather
then cephalosporins for the treatment of Shigella dysentery.12
These results show that treatment of childhood illnesses in
South Africa appears to be appropriate in terms of most drug
choices; however, there seems to be prolonged antibiotic use
for some illnesses which could be contributing to increasing
antibiotic resistance levels. The low response to the survey was
disappointing but not unexpected as no incentives or
reminders were offered to physicians for completing the
survey. In addition, to encourage more ‘open’ reporting of
treatment practices the names of respondents were not
collected, and therefore we could not trace and resurvey those
paediatricians who did not return the questionnaires.
Paediatricians already concerned about antibiotic resistance
levels may have been more likely to answer the survey, and
thus the results may not reflect the treatment practices of all of
South African paediatricians.
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